VERICIGUAT

Other

Brand names: VERQUVO

Oral

Mechanism of Action

12.1 Mechanism of Action Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Indications

in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] . VERQUVO is a soluble guanylate cyclase (sGC) stimulator

indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics

in adults with symptomatic chronic HF and ejection fraction less than 45%. ( 1 )

Contraindications

• 7.1 ) Pregnancy ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS 5
Advise females of reproductive potential of the potential risk to a fetus

Known Side Effects

8 documented side effects by frequency

Low Blood Pressure

>10%

Dizziness

1-10%

Fatigue

1-10%

General Unwellness

0.1-1%

Shortness of Breath

0.1-1%

Nausea

0.1-1%

Weakness

0.1-1%

Diarrhea

0.1-1%

Community Discussions

No community discussions found for VERICIGUAT yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral